What's going on with the Phase 2 ZEN-3694 mCRPC trial?

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

What's going on with the Phase 2 ZEN-3694 mCRPC trial?

posted on Jul 20, 2019 08:39AM

It seems like it has been forever since we've heard an update on the mCRPC trial for ZEN-3694 in combination with enzalutamide. The last Zenith Corporate Update and the AACR poster were about 4 months ago and the only news releases this year were for the TNBC trial. The ClinicalTrials.gov listing for the mCRPC trial still lists the trial as "Active, not recruiting" but the listing hasn't been updated since April 19, 2019. But in the current listing, it indicates that the estimated study completion date as June 2019. Will Zenith file updated MD&A and financials by end of July?